在患有急性淋巴细胞白血病的患者中,可能会出现波纳替尼诱导的 papilledema
Jared A Moon1, Eileen C Bowden1, Moe H Aung1
1Mitchel and Shannon Wong Eye Institute, Dell Medical School at the University of Texas at Austin, 1601 Trinity St., Bldg. B, Stop Z0900, Austin, TX, 78712, USA.
American journal of ophthalmology case reports
|December 11, 2023
概括
本病例报告详细介绍了可能的乳腺炎,这是急性淋巴细胞白血病治疗波纳替尼 (铁氨酸激酶抑制剂) 的罕见副作用. 使用阿西塔佐胺的治疗成功地解决了视觉障碍和视觉盘.
科学领域:
- 在瘤学瘤学.
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 越来越多地用于治疗白血病.
- 乳头是一种罕见但严重的不良反应,与一些TKI相关.
- 本报告重点介绍了一例与波纳替尼治疗相关的乳头炎.
研究的目的:
- 报告在患有急性淋巴细胞白血病的患者中首例可能发生的波纳替尼诱导的乳头炎.
- 强调识别和管理与新型癌症疗法相关的罕见不良事件的重要性.
- 为了记录使用阿西塔佐胺的成功管理波纳替尼布诱导的 papilledema.
主要方法:
- 一名48岁的患有急性淋巴细胞白血病的男性在移植干细胞后开始治疗ponatinib后出现视力障碍.
- 诊断工作包括汉弗雷视觉现场测试,神经成像,腰部穿刺,裂口灯检查,扩展性脑镜检查 (DFE) 和视网膜神经纤维层 (OCT-RNFL) 的光学连贯性断层扫描.
- 该患者每天两次服用500毫克口服乙胺,并在三个月后进行后续评估.
主要成果:
- 患者出现视觉清晰度下降和视觉盘 (右眼的360度模糊,左眼的270度) 通过DFE证实,并在OCT-RNFL上增加了RNFL厚度.
- 神经成像显示部分空腹的部,腰部穿刺显示开口压力在正常的上限,没有其他异常.
- 在接受阿西塔佐拉米德治疗后,患者报告视觉症状的消失,重复检查证实视觉盘的消失.
结论:
- 这一案例代表了与波纳替尼治疗相关的第一例可能的 papilledema 的记录.
- 这些发现扩大了对TKI诱导的 papilledema的理解,并建议用acetazolamide作为一种有效的治疗选择.
- 早期识别和适当的治疗对于在波纳替尼治疗期间出现视觉症状的患者至关重要.
关键词:
急性淋巴细胞白血病 (Acute Lymphocytic Leukemia) 是一种急性淋巴细胞白血病.内高血压是什么意思纸发的情况波纳替尼布 (Ponatinib) 是一种铁氨酸激酶抑制剂 铁氨酸激酶抑制剂更多相关视频
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
167
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
167